Skip to main content

Table 2 Characteristics of the included studies for target AUC/MIC based on effectiveness

From: The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing

Study Design of study Country Duration of study Age of patients Patient’s condition Definition of AUC values Target AUC/MIC breakpoint
Zelenitsky 2013 [40] Retrospective Canada, America, Saudi Arabia 1996–2005 ≥18
Mean ± SD: 55.9 ± 16.7
MRSA-associated septic shock Values calculated (i) within the first 72 h of therapy based on the measured and extrapolated serum levels, and (ii) at steady-state using the daily dose divided by the population pharmacokinetic model derived vancomycin clearance ≥ 451
Ghosh 2014 [22] Retrospective Australia 2006–2012 > 18
Median (range): 64.6 (22–95)
MRSA bacteremia D/(CLcr × 0.79) + 15.4] × 0.06 ≥ 398
Jung 2014 [41] Retrospective Korea 2009–2012 ≥18
Median (IQR):
69 (34–93)
MRSA bacteremia Values estimated fitting vancomycin serum levels to a two-compartment volume clearance model using the maximum a posteriori probability Bayesian approach ≥ 398.5
Song 2015 [23] Prospective Korea 2005–2007 ≥18
Median (IQR):
67 (53–75)
MRSA bacteremia The total vancomycin dose in milligrams for 24 h over the vancomycin clearance ≥ 392.7
Makmor-bakry 2019 [42] Retrospective Malaysia N/A ≥18
Mean ± SD: 59.2 ± 14.5
MRSA bacteremia Values estimated from the trough level and published vancomycin population PK values ≥ 400
  1. D vancomycin dosage in mg/24 h, CLcr estimated creatinine clearance, N/A not available